Allergan recalls Refresh, FML, Blephamide eye drops

Article

Allergan recently issued a voluntary U.S. recall of its Refresh Lacri-Lube, Refresh P.M., FML (fluorometholone ophthalmic ointment) 0.1%, and Blephamide (sulfacetamide sodium and prednisolone acetate ophthalmic ointment) 10%/0.2% due to customer complaints of small black particles at the time of use.

Dublin-Allergan recently issued a voluntary U.S. recall of its Refresh Lacri-Lube, Refresh P.M., FML (fluorometholone ophthalmic ointment) 0.1%, and Blephamide (sulfacetamide sodium and prednisolone acetate ophthalmic ointment) 10%/0.2% due to customer complaints of small black particles at the time of use.

According to Allergan, the black particle is part of the cap and can be created by the action of unscrewing the cap from the aluminum tube and potentially introduced into the product.

The company says the reported adverse events include:

• Foreign body in the eye

• Eye irritation

• Ocular discomfort

• Product contamination

• Superficial eye injury

• Eye pain

• Eye swelling

• Blurred vision

Allergan is recalling specific lots and does not affect any other Refresh or Allergan products. To see a complete list of the recalled lot numbers, CLICK HERE. The lot number and expiration date can be found on the bottom flap of the carton with the safety seal and on the crimp seal of the product tube.

If a patient experiences eye pain, swelling, ocular discomfort or irritation after using any of the recalled products, Allergan says the patient should contact a healthcare provider.

For any questions regarding product returns, contact GENCO at 877-674-2087 from 7 a.m. to 5 p.m. CST. For questions regarding credit or reimbursements, contact Allergan at 1-800-811-4148 from 7 a.m. to 5 p.m. PST. 

Related: Keep your patients safe during the CDC's Contact Lens Health Week

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Matt Jones, OD; Matt Burns, OD; and Joe Sugg, OD; detailed what optometrists can expect to change when HB 1353's regulations are enacted later this year.
Arkansas Optometric Association legislative cochairs Matt Jones, OD; Matt Burns, OD; and Joe Sugg, OD, discuss their involvement in their bill and provide context for its relevance.
Elise Kramer, OD, FAAO, FSLS, describes her take on a multidisciplinary approach to dry eye
Dana Shannon, OD, FAAO, shares pearls on spotting red flags in need of referral and enhancing patient care with follow-up compliance.
Dana Shannon, OD, FAAO, detailed a lecture she gave at the NOA Midwestern Symposium earlier this month.
CRU 2025 provided the latest insights regarding glaucoma, dry eye disease, retina, myopia, neurotrophic keratitis, and keratoconus.
Rachelle Lin, OD, MS, FAAO
Paul Karpecki, OD, FAAO
Melissa Barnett, OD, FAAO, FSLS, FBCLA, gave 2 presentations alongside other ODs and MDs at CRU 2025.
Rachelle Lin, OD, MS, FAAO, at CRU Eye Symposium 2025
© 2025 MJH Life Sciences

All rights reserved.